Dimensional Fund Advisors LP Makes New Investment in Lyell Immunopharma, Inc. $LYEL

Dimensional Fund Advisors LP acquired a new position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 47,888 shares of the company’s stock, valued at approximately $959,000.

Several other large investors have also made changes to their positions in LYEL. Invesco Ltd. bought a new position in shares of Lyell Immunopharma in the 4th quarter worth $3,036,000. MWG Caph Ltd acquired a new position in shares of Lyell Immunopharma in the fourth quarter valued at approximately $31,030,000. ExodusPoint Capital Management LP bought a new position in Lyell Immunopharma during the 4th quarter worth about $262,000. Barclays PLC raised its position in Lyell Immunopharma by 1,239.5% in the 4th quarter. Barclays PLC now owns 15,967 shares of the company’s stock valued at $491,000 after buying an additional 14,775 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Lyell Immunopharma in the fourth quarter valued at approximately $2,257,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Trading Up 1.5%

Shares of NASDAQ LYEL opened at $13.95 on Friday. The firm’s 50-day moving average price is $13.47 and its 200-day moving average price is $18.64. Lyell Immunopharma, Inc. has a 1-year low of $10.49 and a 1-year high of $45.00. The firm has a market capitalization of $341.77 million, a P/E ratio of -1.09 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, topping the consensus estimate of ($1.94) by $0.02. The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. Equities research analysts forecast that Lyell Immunopharma, Inc. will post -7.18 EPS for the current year.

Wall Street Analysts Forecast Growth

LYEL has been the topic of several analyst reports. Robert W. Baird set a $49.00 target price on Lyell Immunopharma and gave the stock an “outperform” rating in a report on Thursday, April 30th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of Lyell Immunopharma in a report on Tuesday, June 9th. Citigroup reiterated a “market outperform” rating on shares of Lyell Immunopharma in a research report on Friday. Royal Bank Of Canada set a $34.00 price target on shares of Lyell Immunopharma in a research report on Friday. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $34.00 price target on shares of Lyell Immunopharma in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.86.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.